Oric End Period Cash Flow vs Net Income Analysis
| ORIC Stock | USD 9.59 0.47 5.15% |
Oric Pharmaceuticals financial indicator trend analysis is much more than just breaking down Oric Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Oric Pharmaceuticals is a good investment. Please check the relationship between Oric Pharmaceuticals End Period Cash Flow and its Net Income accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oric Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For information on how to trade Oric Stock refer to our How to Trade Oric Stock guide.
End Period Cash Flow vs Net Income
End Period Cash Flow vs Net Income Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Oric Pharmaceuticals End Period Cash Flow account and Net Income. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Oric Pharmaceuticals' End Period Cash Flow and Net Income is -0.33. Overlapping area represents the amount of variation of End Period Cash Flow that can explain the historical movement of Net Income in the same time period over historical financial statements of Oric Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Oric Pharmaceuticals' End Period Cash Flow and Net Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which End Period Cash Flow of Oric Pharmaceuticals are associated (or correlated) with its Net Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income has no effect on the direction of End Period Cash Flow i.e., Oric Pharmaceuticals' End Period Cash Flow and Net Income go up and down completely randomly.
Correlation Coefficient | -0.33 |
| Relationship Direction | Negative |
| Relationship Strength | Insignificant |
End Period Cash Flow
Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Oric Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Oric Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most indicators from Oric Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Oric Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oric Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For information on how to trade Oric Stock refer to our How to Trade Oric Stock guide.The current year's Enterprise Value is expected to grow to about 581.3 M, whereas Selling General Administrative is forecasted to decline to about 17.5 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 141K | 2.6M | 3.0M | 3.2M | Net Interest Income | 141K | 2.6M | 3.0M | 3.2M |
Oric Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Oric Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Oric Pharmaceuticals fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Other Current Liab | 5.2M | 8.2M | 11.3M | 11.4M | 16.8M | 8.7M | |
| Total Current Liabilities | 5.4M | 9.0M | 15.2M | 15.4M | 20.5M | 11.1M | |
| Net Tangible Assets | (90.1M) | 289.8M | 273.0M | 222.4M | 255.7M | 268.5M | |
| Retained Earnings | (92.7M) | (166.4M) | (245.1M) | (334.2M) | (434.9M) | (413.2M) | |
| Accounts Payable | 152K | 757K | 1.9M | 1.3M | 944K | 1.0M | |
| Other Assets | 0.0 | 319K | 521K | 517K | 594.6K | 433.8K | |
| Total Current Assets | 90.0M | 296.7M | 240.5M | 210.5M | 212.6M | 176.1M | |
| Property Plant Equipment | 2.2M | 2.0M | 2.4M | 3.3M | 3.7M | 2.8M | |
| Total Assets | 94.1M | 299.0M | 298.6M | 247.2M | 252.0M | 226.9M | |
| Total Stockholder Equity | 88.0M | 289.8M | 273.0M | 222.4M | 224.1M | 189.3M | |
| Property Plant And Equipment Net | 2.2M | 2.0M | 2.4M | 3.3M | 12.0M | 12.6M | |
| Net Debt | (89.2M) | (78.4M) | (224.1M) | (64.2M) | (13.2M) | (13.8M) | |
| Cash | 89.2M | 78.4M | 226.0M | 66.8M | 23.4M | 22.2M | |
| Non Current Assets Total | 4.1M | 2.3M | 58.1M | 36.7M | 39.4M | 26.3M | |
| Non Currrent Assets Other | 1.9M | 319K | 12.3M | 11.5M | 552K | 524.4K | |
| Cash And Short Term Investments | 89.2M | 293.6M | 237.0M | 206.3M | 208.2M | 197.4M | |
| Common Stock Shares Outstanding | 29.9M | 21.9M | 38.0M | 39.7M | 51.5M | 36.7M | |
| Liabilities And Stockholders Equity | 94.1M | 299.0M | 298.6M | 247.2M | 252.0M | 226.9M | |
| Non Current Liabilities Total | 765K | 219K | 10.5M | 9.4M | 7.5M | 7.1M | |
| Capital Surpluse | 2.6M | 456.2M | 518.2M | 557.9M | 641.5M | 338.0M | |
| Other Current Assets | 840K | 3.1M | 7.1M | 4.2M | 4.4M | 3.8M | |
| Other Stockholder Equity | 180.7M | 157.2M | 518.2M | 557.9M | 658.8M | 380.7M | |
| Total Liab | 6.1M | 9.2M | 25.7M | 24.8M | 27.9M | 27.3M | |
| Net Invested Capital | 88.0M | 289.8M | 273.0M | 222.4M | 224.1M | 189.3M | |
| Property Plant And Equipment Gross | 2.2M | 2.0M | 7.4M | 9.0M | 9.4M | 6.0M | |
| Accumulated Other Comprehensive Income | (178.1M) | (31K) | (103K) | (1.3M) | 258K | 270.9K | |
| Net Working Capital | 84.6M | 287.7M | 225.4M | 195.1M | 192.1M | 188.1M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Oric Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oric Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oric Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oric Pharmaceuticals Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oric Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For information on how to trade Oric Stock refer to our How to Trade Oric Stock guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oric Pharmaceuticals. If investors know Oric will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oric Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.82) | Return On Assets (0.29) | Return On Equity (0.46) |
The market value of Oric Pharmaceuticals is measured differently than its book value, which is the value of Oric that is recorded on the company's balance sheet. Investors also form their own opinion of Oric Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Oric Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oric Pharmaceuticals' market value can be influenced by many factors that don't directly affect Oric Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oric Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oric Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oric Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.